Since opening in early 2010, The Center for Cancer Care at Sherman Health has been a powerful ally for patients and families touched by cancer throughout the region.
Located on the new Sherman Hospital campus, The Center offers both outpatient and inpatient services, including Diagnostics, Infusion Therapy, and Medical, Radiation and Surgical Oncology in a beautiful, state-of-the-art facility custom-designed for healing.
But more than a place to go for treatment, The Center for Cancer Care at Sherman Health has become a community all its own -- where people can connect and find the support they need to power through.
Patients and loved ones benefit from:
- More than 15,000 square feet of space
- Private and shared treatment rooms -- all with their own televisions -- giving you the option of receiving cancer chemotherapy separately or together with other patients
- A resource library, where every member of the community can come to research and learn about cancer care and prevention
- A boutique sponsored by the American Cancer Society that provides free wigs and professional styling, breast prosthetic fittings and more
- A meditation room
- Dedicated parking and a separate entrance, so you can access the care you need without having to go through the Hospital
For more information on the Center for Cancer Care at Sherman Health, visit ShermanCancerCare.com.
We have been involved in clinical research for over 15 years.
We conduct Phase II, III, and IV studies including symptom management and cancer prevention studies.
We have worked with the following Sponsors/CROs:
- MD Anderson
- SWOG
- NSABP
- ECOG
- GOG
- URCC
- CALBG
- CTSU
C. Yeshwant, M.D.
Area of Expertise: Hematology/Oncology
S. Nabrinsky, M.D.
Area of Expertise: Hematology/Oncology
A. Zahir, M.D.
Area of Expertise: Hematology/Oncology
A. Desai, M.D.
Area of Expertise Hematology/Oncology
Janeen V. Bazan
Oncology Research Nurse Program Coordinator, RN, OCN, BSN, CCRP
Certified Clinical Research Professional
Over 15 years experience
We also have:
- A team of 100% Oncology Certified Nurses
- Outcomes Management
- Resource Analyst
- Oncology Social Worker
- Oncology Dietitian
- Nurse Navigator
- Breast Cancer Nurse Navigator
People
Physicians: 645
Registered Nurses: 642
Employees: 2071
Highlights (Annually)
Births: 2,700
Emergency Department Visits: 48,000
Open Heart Surgeries: 374
Outpatient Surgeries: 64,153
Inpatient Surgeries: 6,778
Cardiology/Vascular Diseases
Endocrinology
Neurology
Obstetrics/Gynecology
Oncology
Janeen V. Bazan
Oncology Research Nurse Program Coordinator
Sherman Health
1425 North Randall Road
Elgin, IL 60123
USA
847-429-2907 or 224-783-2907
847-429-3071 or 224-783-3071 (fax)
Janeen.Bazan@shermanhospital.org
- A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)
- CALGB 40502 A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound NAB-Paclitaxel or Ixabepilone Combined with Bevacizumab as First- Line Therapy for Locally Recurrent or Metastatic Breast Cancer
- ECOG E5103 A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
- GOG-0252 Phase III Clinical Trial of Bevacizumab with IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
- MDA 2006-0841 Randomized, Double-blind, Placebo-controlled Trial of Palonosetron/Dexamethasone with or without Dronabinol for the Prevention of Chemotherapy-induced Nausea and Vomiting after Moderately Emetogenic Chemotherapy
- MDA 2007-0914 A A Multi-Center Study in Patients Undergoing Anthracycline-Based Chemotherapy to Assess the Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment
- NSABP Protocol P-5: Statin Polyp Prevention Trial in Patients with Resected Colon Cancer
- Randomized phase III study for stage II colon cancer at high risk for recurrence Comparing 5-FU, leucovorin and Oxalplatin versus 5-FU, leucovorin, oxaliplatin and bevacizumab to determine prospectively the prognostic value of molecular markers
- S0715, Randomized Placebo-Controlled Trial of Acetyl L-Carnitine for the Prevention of Taxane Induced Neuropathy
- SWOG S0221 Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node- Positive or High-Risk Node-Negative Breast Cancer
- SWOG S0816 A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma using Early Interim FDG-PET Imaging